This firm currently holds 8.68
M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest Acer Therapeutics is not taking enough advantage from borrowing. The company has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Acer Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Acer Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acer Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acer Therapeutics to invest in growth at high rates of return. When we think about Acer Therapeutics' use of debt, we should always consider it together with cash and equity.
We provide trade advice to complement the prevailing
expert consensus on Acer Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of Acer Therapeutics using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Acer Therapeutics based exclusively on its
fundamental and basic
technical indicators. By analyzing Acer Therapeutics's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Acer Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Acer Therapeutics. We calculate exposure to Acer Therapeutics's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Acer Therapeutics's related companies.
Watch out for price decline
Please consider monitoring Acer Therapeutics on a daily basis if you are holding a position in it. Acer Therapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Acer Therapeutics stock to be traded above the $1 level to remain listed. If Acer Therapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Acer Therapeutics Investment Alerts
Acer investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Acer Therapeutics performance across your portfolios.Please check all
investment alerts for Acer
Acer Therapeutics Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Acer value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Acer Therapeutics competition to find
correlations between indicators driving the intrinsic value of Acer.
What is driving Acer Therapeutics Investor Appetite?
The latest price spike of Acer Therapeutics could raise concerns from retail investors as the firm is trading at a share price of
3.18 on
157,973 in volume. The company directors and management may have good odds in positioning the firm resources to exploit
market volatility in
January. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.54. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Acer Therapeutics partners.
| 2016 | 2021 | 2022 (projected) |
Revenues USD | 1.26 M | 1.45 M | 1.68 M | Revenues | 2.91 M | 1.13 M | 1.38 M |
Acer Therapeutics Earnings Before Interest Taxes and Depreciation Amortization EBITDA is relatively stable at the moment. Also, Acer Therapeutics Revenue Per Employee is relatively stable at the moment.
Our Acer Therapeutics analysis connotes possible reversion in January
The total risk alpha is down to 0.87 as of today. Acer Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Acer Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Acer Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Acer Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Acer Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Final Perspective on Acer Therapeutics
While some companies in the biotechnology industry are either recovering or due for a correction, Acer Therapeutics may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 16th of December 2022, we believe that at this point, Acer Therapeutics is risky with
below average probability of financial unrest within the next 2 years. From a slightly different point of view, the entity appears to be
undervalued. Our actual 90 days 'Buy-vs-Sell' recommendation on the enterprise is
Strong Buy.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Acer Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
